Persistent URL of this record https://hdl.handle.net/1887/3182678
Documents
-
- Download
- e755.full
- Publisher's Version
- open access
- Full text at publishers site
In Collections
This item can be found in the following collections:
Minimal manifestation status and prednisone withdrawal in the MGTX trial
- All authors
- Lee, I.; Kuo, H.C.; Aban, I.B.; Cutter, G.R.; McPherson, T.; Kaminski, H.J.; Sussman, J.; Strobel, P.; Oger, J.; Cea, G.; Heckmann, J.M.; Evoli, A.; Nix, W.; Ciafaloni, E.; Antonini, G.; Witoonpanich, R.; King, J.O.; Beydoun, S.R.; Chalk, C.H.; Barboi, A.C.; Amato, A.A.; Shaibani, A.I.; Katirji, B.; Lecky, B.R.F.; Buckley, C.; Vincent, A.; Dias-Tosta, E.; Yoshikawa, H.; Waddington-Cruz, M.; Pulley, M.T.; Rivner, M.H.; Kostera-Pruszczyk, A.; Pascuzzi, R.M.; Jackson, C.E.; Verschuuren, J.J.G.; Massey, J.M.; Kissel, J.T.; Werneck, L.C.; Benatar, M.; Barohn, R.J.; Tandan, R.; Mozaffar, T.; Conwit, R.; Minisman, G.; Sonett, J.R.; Wolfe, G.I.; MGTX Study Grp
- Date
- 2020-08-11
- Journal
- Neurology
- Volume
- 95
- Issue
- 6
- Pages
- E755 - E766